Ligandrol

• Data sheet: View or download
• MSDS: View or download

Ligandrol (LGD-4033) is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (Ki of 1 nM) and selectivity. IC50 value: 1 nM (Ki, for androgen receptor) Target: androgen receptor in vitro: Ligandrol (LGD-4033), a novel nonsteroidal oral, selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. in vivo: Ligandrol (LGD-4033) has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate In animal models. Ligandrol (LGD-4033) is well tolerated, has a long elimination half-life and dose-proportional accumulation upon multiple dosing. Ligandrol (LGD-4033) is safe, has favorable pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen.